VA
TSHA icon

VR Adviser’s Taysha Gene Therapies TSHA Stock Holding History

VR Adviser’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,225,180
Closed -$5.58M – 41
2024
Q4 		$5.58M Sell
3,225,180
-5,774,820
-64% -$12M 0.38% 29
2024
Q3 		$18.1M Hold
9,000,000
– – 0.95% 26
2024
Q2 		$20.2M Hold
9,000,000
– – 1.28% 24
2024
Q1 		$25.8M Sell
9,000,000
-1,412,872
-14% -$2.94M 1.23% 23
2023
Q4 		$18.4M Sell
10,412,872
-4,031,572
-28% -$8.04M 1.26% 24
2023
Q3 		$45.6M Buy
+14,444,444
New +$27M 4.81% 5
2021
Q2 		– Sell
-120,649
Closed -$2.45M – 34
2021
Q1 		$2.45M Buy
120,649
+12,667
+12% +$343K 0.27% 27
2020
Q4 		$2.87M Hold
107,982
– – 0.42% 24
2020
Q3 		$2.6M Buy
+107,982
New +$2.54M 0.51% 20

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VR Adviser's TSHA Position: Q1 2025 in Review

VR Adviser sold out of Taysha Gene Therapies (TSHA) in Q1 2025, closing a stake of 3,225,180 shares — an estimated $5.58M sold.

VR Adviser first reported a position in TSHA in Q3 2020 and held it in 9 quarters. The position peaked at $45.6M in Q3 2023. 127 funds tracked by Wall St. Rank hold TSHA as of Q1 2025.

  • VR Adviser reported no remaining Taysha Gene Therapies position as of Q1 2025 after selling out during the quarter.
  • VR Adviser sold 3,225,180 Taysha Gene Therapies shares in Q1 2025, an estimated $5.58M.
  • VR Adviser first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 9 quarters.
  • VR Adviser's Taysha Gene Therapies position peaked at $45.6M in Q3 2023.
  • 127 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2025.

Based on VR Adviser's 13F filing for Q1 2025, filed 15 May 2025.